A broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms and its application

By screening CP5, a broad-spectrum antimicrobial peptide from pig gut microbiota, the problems of low bioavailability, insufficient salt ion inhibitory activity, and broad spectrum of existing antimicrobial peptides in livestock farming have been solved, enabling the preparation of antimicrobial agents that effectively inhibit multiple pathogens and have high safety.

CN122790045BActive Publication Date: 2026-11-10ZHEJIANG UNIV OF TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611231500.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-08-14
Publication Date
2026-11-10
Estimated Expiration
2046-08-14

AI Technical Summary

Technical Problem

Existing antimicrobial peptides have problems such as low bioavailability, easy degradation by intestinal enzymes, salt ion inhibition of activity, insufficient exploitation of pig intestinal microbial resources, and lack of broad-spectrum activity, making them difficult to be effectively applied in complex in vivo and in vitro environments.

Method used

A broad-spectrum antimicrobial peptide, CP5, with the amino acid sequence SEQ ID NO.1, was screened from pig intestinal microorganisms. It contains 29 L-type amino acids, adsorbs onto bacterial membranes via electrostatic attraction, exhibits high cationic properties, adapts to high-salt environments, and is synthesized using Fmoc solid-phase synthesis. It is suitable for preparing antimicrobial agents.

Benefits of technology

Antimicrobial peptide CP5 exhibits significant inhibitory activity against a variety of pathogens, has excellent salt ion stability, high safety, and is easy to mass-produce, making it suitable for preparing antimicrobial agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122790045B_ABST
    Figure CN122790045B_ABST
Patent Text Reader

Abstract

This invention discloses a broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms and its applications. The antimicrobial peptide CP5 consists of 29 L-amino acids. This peptide exhibits significant inhibitory activity against Gram-positive / negative bacteria such as *Enterococcus faecalis* POBX 305-2 and *Enterococcus faecium* POBX 205-1, with inhibitory effects superior to the human antimicrobial peptide LL-37 against some strains. The minimum inhibitory concentration (MIC) against *Enterococcus faecalis* remains relatively stable at low to medium salt concentrations, making it suitable for feed and the intestinal environment. Safety evaluations show extremely low hemolysis and cytotoxicity, and good biocompatibility. This peptide can be synthesized at low cost using the Fmoc solid-phase chemical method and can be widely used in antibiotic alternatives, veterinary drugs, food preservatives, and antimicrobial agents for medical consumables, showing broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of polypeptide application technology, specifically relating to a broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms and its applications. Background Technology

[0002] The long-term and widespread use of antibiotics in livestock farming has led to the proliferation of drug-resistant bacteria and drug residues in animals, posing a serious threat to food safety and public health. To address these challenges, developing safe and effective antibiotic alternatives has become an inevitable trend for the green development of the livestock industry. Antimicrobial peptides, due to their unique membrane action mechanism, possess broad-spectrum antimicrobial activity and a low risk of resistance induction, and are considered one of the most promising alternatives to feed antibiotics. However, existing antimicrobial peptides still face several problems when used as feed additives or animal health products: firstly, some antimicrobial peptides derived from plants or insects are easily degraded by proteases in the animal gut, resulting in low bioavailability; secondly, sodium (Na2+) is commonly found in animal intestines and feed matrices. + Mg 2+ Cationic substances competitively inhibit the electrostatic binding of antimicrobial peptides to bacterial membranes, causing the antimicrobial activity of most antimicrobial peptides to drop sharply in high-salt environments, making them difficult to adapt to complex in vivo and in vitro application environments. Thirdly, the exploration of the huge resource pool of porcine intestinal microorganisms is still insufficient. Existing products are mostly focused on the inhibition of single bacterial species (such as Escherichia coli), and there is a lack of broad-spectrum active molecules that can simultaneously cover Gram-positive and Gram-negative bacteria.

[0003] The pig gut is home to a vast array of microorganisms, making it a valuable resource for screening novel bioactive substances. Although the human antimicrobial peptide LL-37 exhibits broad-spectrum antibacterial activity, its short half-life in animals and significant loss of activity in high-salt-concentration feeds and intestinal environments limit its widespread application in animal husbandry. Therefore, screening and identifying a novel antimicrobial peptide from the unique habitat of the pig gut microbiota, possessing excellent broad-spectrum antimicrobial activity, outstanding salt ion stability, and low immunogenicity, is of significant practical importance and application value for developing next-generation green and safe animal-specific anti-infective agents and antibiotic-alternative feed additives. Summary of the Invention

[0004] To address the above problems, the present invention aims to provide a broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms and its applications.

[0005] The specific technical solution is as follows:

[0006] A broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms, the amino acid sequence of which is shown in SEQ ID NO.1, consists of 29 L-type amino acids.

[0007] Application of CP5, a broad-spectrum antimicrobial peptide derived from porcine intestinal microorganisms, in the preparation of antimicrobial agents.

[0008] Furthermore, the bacteria targeted by the antimicrobial peptides include self-isolated Enterococcus faecalis strain POBX 305-2, self-isolated Enterococcus faecalis strain POBX 205-1, Staphylococcus aureus standard strain (Staphylococcus aureus ATCC 6538), methicillin-resistant Staphylococcus aureus clinical isolate (Methicillin-resistant Staphylococcus aureus USA 300), Pseudomonas aeruginosa (Pseudomonas aeruginosa ATCC 27853), Acinetobacter baumannii (Acinetobacter baumannii ATCC 19606), Escherichia coli (Escherichia coli ATCC 25922), Salmonella typhimurium (Salmonella typhimurium 14028S), and Klebsiella pneumoniae (Klebsiella pneumoniae ATCC 13883).

[0009] The beneficial effects of this invention are as follows:

[0010] 1) Broad antibacterial spectrum: The antimicrobial peptide CP5 has significant inhibitory activity against common pathogens (including standard strains such as Enterococcus faecalis isolate POBX 305-2, Enterococcus faecalis isolate POBX 205-1, and S. typhimurium 14028S), with minimum inhibitory concentration (MIC) values ​​of 4~256 μmol / L.

[0011] 2) Excellent salt tolerance: In Na + (0.125-2 mg / mL) and Mg 2+ Within a certain concentration range of (25-100 μg / mL), the MIC value for Enterococcus faecalis remains basically unchanged, indicating good compatibility with feed and intestinal environment.

[0012] 3) High safety: The hemolysis rate is extremely low at effective concentrations, and it has low toxicity to porcine small intestinal epithelial cells (IPEC-J2) and human bronchial epithelial cells (BEAS-2B), with a wide safety window.

[0013] 4) Easy to scale up: Composed of 29 natural amino acids with a well-defined sequence, it is suitable for solid-phase peptide synthesis (fmocstrategy) and has low cost. Attached Figure Description

[0014] Figure 1This is a graph showing the MIC determination results of the antimicrobial peptide CP5 of the present invention against different pathogens.

[0015] Figure 2 This is a graph showing the hemolytic phenomenon of the antimicrobial peptide CP5 of this invention.

[0016] Figure 3 The graph shows the hemolysis rate of the antimicrobial peptide CP5 of this invention.

[0017] Figure 4 This is a graph showing the cytotoxicity evaluation results of the antimicrobial peptide CP5 of this invention against mammalian cells BEAS-2B.

[0018] Figure 5 This is a graph showing the cytotoxicity evaluation results of the antimicrobial peptide CP5 of this invention against mammalian IPEC-J2 cells;

[0019] Figure 6 The antimicrobial peptide CP5 of this invention is effective against different concentrations of Na. + The results of MIC determination of Enterococcus faecalis POBX 205-1 under the specified conditions are shown in the figure.

[0020] Figure 7 The antimicrobial peptide CP5 of this invention is effective against different concentrations of Mg. 2+ The results of MIC determination of Enterococcus faecalis POBX 205-1 under the specified conditions. Detailed Implementation

[0021] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0022] Example 1

[0023] Synthesis of antimicrobial peptide CP5

[0024] The antimicrobial peptide CP5 was screened from the genome of porcine gut microbes and synthesized using Fmoc solid-phase synthesis by a specialized peptide synthesis company based on its sequence. become It was artificially synthesized and purified by reversed-phase high-performance liquid chromatography (RP-HPLC) to a purity of over 95%.

[0025] The synthesized antimicrobial peptides were molecular weight identified by liquid chromatography-mass spectrometry (LC-MS), confirming that their molecular weight was consistent with the theoretical molecular weight. The purified antimicrobial peptides were lyophilized and stored. Before use, the antimicrobial peptides were dissolved in 1% DMSO with sterile ultrapure water to the required concentration.

[0026] The amino acid sequence of the antimicrobial peptide CP5 is shown in SEQ ID NO.1: MNLVRRLKHQKVSKRIYKRIQ-IYKLNYGA (Met-Asn-Leu-Val-Arg-Arg-Leu-Lys-His-Gln-Lys-Val-Ser-Lys-Arg-Ile-Tyr-Lys-Arg-Ile-Gln-Ile-Tyr-Lys-Leu-Asn-Tyr-Gly-Ala).

[0027] The amino acid sequence of the antimicrobial peptide CP5 contains six arginine (Arg) and two lysine (Lys) residues, resulting in a theoretical isoelectric point (pI) as high as 10.78, which endows it with extremely strong cationic properties. Under neutral pH conditions, CP5 carries a large number of positive charges and can be rapidly adsorbed onto the negatively charged bacterial cell membrane surface (mainly composed of anionic lipids such as phosphatidylglycerol) through electrostatic attraction.

[0028] Example 2

[0029] Antimicrobial peptide MIC assay

[0030] The in vitro antimicrobial activity of the antimicrobial peptide against the tested bacterial strains was initially tested using the micro-broth dilution method. The inhibition rate was calculated by measuring the absorbance at 600 nm, which allowed for a rapid determination of whether the peptide had the ability to inhibit bacterial growth.

[0031] 1) Preparation of bacterial culture: Test strains included POBX 305-2, POBX 205-1, S. aureus ATCC 6538, S. aureus USA 300, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606, E. coli ATCC25922, S. typhimurium 14028S, and K. pneumoniae ATCC 13883. Human antimicrobial peptide LL-37 was used as a positive control peptide, and liquid culture medium was added only as a blank group.

[0032] The bacterial strains were removed from a -80 °C freezer and inoculated onto MHB solid medium using the streak plate method. The medium was then incubated upside down overnight in a 37 °C incubator. A single colony was picked and inoculated into 5 mL of MHB liquid medium. After mixing thoroughly by pipetting, the culture was incubated at 200 rpm for 12 h in a shaker at 37 °C to obtain the seed culture. 5 μL of the seed culture was transferred to 5 mL of fresh MHB liquid medium and cultured in a shaker until the bacterial concentration reached 10⁻⁶. 8 CFU / mL.

[0033] 2) Antibacterial test (peptide concentration gradient: 256~0.25 μmol / L)

[0034] ① Peptide gradient dilution

[0035] Dissolve the peptide in 1% DMSO to a concentration of 10.24 mmol. Add 5 μL of peptide stock solution (10.24 mmol / L) to the first column of a 96-well plate, and add 100 μL of MHB liquid medium to each well. Add 95 μL of MHB liquid medium to the first column, mix thoroughly by pipetting, and then transfer 100 μL of the mixture to the second column. Perform serial dilutions up to the tenth column. After mixing the tenth column, discard 100 μL. Control group: 100 μL MHB liquid medium (to be added later).

[0036] ② Add bacteria

[0037] Dilute the bacterial culture to 1×10⁻⁶ 5 CFU / mL, add 100 μL of bacterial culture to each well;

[0038] ③Cultivation and Detection

[0039] The 96-well plate was incubated in a 37 ℃ incubator for 16 h, and the OD was measured. 600 ;

[0040] ④ Calculation of antibacterial rate

[0041] Formula: Antibacterial rate (%) = (1 - (experimental group)) OD600 - Blank group OD600 ) / (Control group) OD600 - Blank group OD600 ))×100%

[0042] The result is as follows Figure 1 As shown, the results clearly indicate that the antimicrobial peptide CP5 exhibits the best antimicrobial activity against Enterococcus faecalis POBX 205-1, with a MIC value as low as 4 μmol / L; it also shows good antimicrobial activity against other tested Gram-positive and Gram-negative strains, with MIC values ​​ranging from 16 to 256 μmol / L.

[0043] Example 3

[0044] Hemolytic activity evaluation

[0045] The blood compatibility of the antimicrobial peptides of this invention was evaluated using a sheep erythrocyte hemolysis test. Whole blood was pre-cooled to 4 °C, centrifuged (3000 rpm / min, 10 min), and the supernatant was discarded, retaining the bottom erythrocyte pellet. Approximately 5 times the volume of sterile physiological saline was added, and the erythrocytes were gently resuspended. The mixture was centrifuged again, and the supernatant was discarded. This washing process was repeated 4 times until the supernatant was colorless and transparent. Pre-cooled physiological saline was added to prepare a 4% (v / v) erythrocyte suspension, and the mixture was thoroughly mixed. A 1.5 ml EP tube was taken, 1 ml of the erythrocyte suspension was added, and the tube was centrifuged (3000 rpm / min, 10 min), discarding the supernatant. 1 ml of the test drug (antimicrobial peptide CP5) was added to the erythrocyte pellet, and the mixture was gently mixed. The resulting concentrations were 4 μm, 8 μm, 16 μm, 32 μm, 64 μm, 128 μm, and 256 μm, respectively. The mixture was incubated at 37 °C for 3 days. h; Remove the EP tube, centrifuge, visually inspect the supernatant for hemolysis, and take a photograph against a white background (e.g., ...). Figure 2 As shown, no obvious hemolysis was observed, indicating that it has good blood compatibility and application safety; 200 μL of the supernatant from each tube was added to a 96-well plate, and the OD value was measured at a wavelength of 540 nm.

[0046] Sterile saline was used as a negative control, and 0.1% Triton X-100 was used as a positive control. The hemolysis rate was calculated using the following formula: Hemolysis rate (%) = (OD200) / (0.1% Triton X-1 ... 实验组 -OD 阴性组 ) / (OD 阳性组 -OD 阴性组 ))×100%.

[0047] like Figure 3 As shown, experimental results indicate that the antimicrobial peptide CP5 of this invention exhibits a low hemolysis rate within the range of 4-64 μmol / L. The low hemolysis rate exhibited by the antimicrobial peptide CP5 is closely related to its selective cytotoxicity. The surface of mammalian erythrocyte membranes is electrically neutral or weakly negatively charged and lacks anionic lipids specific to bacteria, such as phosphatidylglycerol, making it difficult for the positively charged CP5 to firmly adsorb onto the erythrocyte membrane surface. Simultaneously, the erythrocyte membrane is rich in cholesterol, further enhancing membrane stability and hindering the hydrophobic insertion of CP5. In contrast, bacterial cell membranes are rich in phosphatidylglycerol and lack cholesterol, making them more susceptible to interaction with CP5. This selective recognition mechanism based on membrane composition differences ensures that CP5 effectively kills pathogens while minimizing damage to host erythrocytes, demonstrating excellent blood compatibility.

[0048] Example 4

[0049] Cytotoxicity evaluation

[0050] The toxicity of the antimicrobial peptides of this invention to mammalian cells was evaluated using the CCK-8 assay.

[0051] BEAS-2B and IPEC-J2 cells cultured to the 5th generation were used for experiments. The old culture medium was discarded, the cells were washed with PBS, digested with trypsin, and then counted. The cell suspension density was adjusted to 1×10⁻⁶. 5 Cells / mL. The adjusted cell suspension was evenly spread into 96-well plates at a volume of 100 μL per well. To avoid edge effects, the outermost well of each 96-well plate was blocked with 150 μL of PBS solution and incubated overnight at 37 ℃ in a CO2 incubator. The 96-well plates were then removed, and 10 μL of different concentrations of antimicrobial peptide solution was added to each well (BEAS-2B cells: 256 μmol / L, 128 μmol / L, 64 μmol / L, 32 μmol / L, 16 μmol / L, 8 μmol / L, 4 μmol / L, 2 μmol / L; IPEC-J2 cells: 1024 μmol / L, 512 μmol / L, 256 μmol / L, 128 μmol / L, 64 μmol / L, 32 μmol / L, 16 μmol / L, 8 μmol / L). One blank control and one negative control group were set up for each group. The blank control group contained no cells but only culture medium, while the negative control group contained both cells and culture medium. The 96-well plates were incubated for 12 hours. After incubation, 10 µL of CCK-8 solution was added to each well, and the plates were incubated for 3 hours. The OD values ​​were then measured using a microplate reader. 450 value.

[0052] The formula for calculating cell viability is:

[0053] Cell viability (%) = ((OD) 加药孔 -OD 空白孔 ) / (OD 阴性孔 -OD 空白孔 ))×100%.

[0054] like Figure 4 and Figure 5 As shown in the figure, the experimental results indicate that the antimicrobial peptide CP5 can achieve a survival rate of more than 50% in both cell types at low and medium concentrations (2 μmol / L-64 μmol / L), with low cytotoxicity, indicating good safety.

[0055] The low toxicity of the antimicrobial peptide CP5 to IPEC-J2 cells further confirms its membrane selectivity mechanism. The surface of mammalian epithelial cell membranes is rich in glycocalyx and sialic acid residues. These structures not only mask the negative potential of the membrane surface but also hinder the close contact of antimicrobial peptides through steric hindrance. Furthermore, IPEC-J2 cells possess a sophisticated cholesterol-mediated membrane stabilization mechanism and a highly efficient intracellular repair system, enabling them to promptly repair minor membrane damage caused by non-specific peptide adsorption. Therefore, within a therapeutic window of 2–64 μmol / L, CP5 can effectively distinguish between prokaryotic pathogens and eukaryotic host cells, exhibiting good cellular safety and meeting the safety requirements for feed additives and oral formulations.

[0056] Example 5

[0057] Salt ion stability experiment

[0058] (1) Preparation of bacterial suspension: The process is the same as that for MIC determination. The bacterial suspension used in this experiment is POBX 205-1 bacterial suspension;

[0059] (2) Dissolve and dilute NaCl with HEPES buffer, add 45 μl of salt solution to each well, so that the final concentration of NaCl per plate is 4 mg / ml, 2 mg / ml, 1 mg / ml, 0.5 mg / ml, 0.25 mg / ml, and 0.125 mg / ml, and the final concentration of MgCl2 is 800 μg / ml, 400 μg / ml, 200 μg / ml, 100 μg / ml, 50 μg / ml, and 25 μg / ml.

[0060] (3) Antibacterial test

[0061] After fixing the salt concentration, the peptide concentration was diluted: the peptide was dissolved in 1% DMSO diluted with HEPES buffer to a concentration of approximately 10 mmol, and then serially diluted using 0.5 ml EP tubes. 5 μl of peptide solution was added to each well, resulting in final peptide concentrations of 256 μmol / L, 128 μmol / L, 64 μmol / L, 32 μmol / L, 16 μmol / L, 8 μmol / L, 4 μmol / L, and 2 μmol / L for each column. The POBX 205-1 bacterial culture was diluted to 1×10⁻⁶. 5 CFU / mL, 50 μL of LHB liquid medium and 100 μL of bacterial suspension were added to each well; the blank group contained only the medium, and the control group contained salt solution, bacterial suspension and medium. The 96-well plate was incubated at 37℃ for 16 h, and the OD was measured. 600 .

[0062] (4) Calculation of antibacterial rate

[0063] Formula: Antibacterial rate (%) = (1 - (experimental group)) OD600 - Blank group OD600 ) / (Control group) OD600 - Blank group OD600 ))×100%.

[0064] like Figure 6 and Figure 7 As shown, the experimental results clearly demonstrate that at medium and low salt concentrations (Na... + 0.125 mg / ml - 2 mg / ml; Mg 2 + The MIC of antimicrobial peptide CP5 against Enterococcus faecalis remained essentially unchanged under conditions of 25 μg / ml-100 μg / ml.

Claims

1. A broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms, characterized in that, The amino acid sequence of the antimicrobial peptide CP5 is shown in SEQ ID NO.

1.

2. The broad-spectrum antimicrobial peptide CP5 derived from porcine intestinal microorganisms as described in claim 1, characterized in that, It is composed of 29 L-type amino acids.

3. The application of CP5, a broad-spectrum antimicrobial peptide derived from porcine intestinal microorganisms as described in claim 1 or 2, in the preparation of antimicrobial agents, characterized in that, The antibacterial agent targets the following bacteria: Enterococcus faecalis (POBX 305-2, POBX 205-1, Staphylococcus aureus standard strain ATCC 6538, methicillin-resistant Staphylococcus aureus clinical isolate USA300, Pseudomonas aeruginosa ATCC 27853, Acinetobacter baumannii ATCC 19606, Escherichia coli ATCC 25922, Salmonella typhimurium 14028S, and Klebsiella pneumoniae ATCC 13883.

Citation Information

Patent Citations

  • Swine antibacterial peptide PR-39 mutant as well as preparation method and application thereof

    CN104356222A

  • Broad-spectrum antibacterial peptide KTR and application thereof

    CN116253782A